What are the indications, dosing regimen, contraindications, precautions, and patient counseling recommendations for Farxiga (dapagliflozin)?

Farxiga (Dapagliflozin): Clinical Overview

Farxiga is a highly effective SGLT2 inhibitor with four FDA-approved indications: chronic kidney disease at risk of progression, heart failure (regardless of ejection fraction), reducing heart failure hospitalization in type 2 diabetes with cardiovascular disease/risk factors, and glycemic control in type 2 diabetes (adults and pediatric patients ≥10 years). 1

FDA-Approved Indications

Farxiga is indicated for:

• Chronic kidney disease at risk of progression: To reduce sustained eGFR decline, ESKD, cardiovascular death, and heart failure hospitalization 1
• Heart failure: To reduce cardiovascular death, heart failure hospitalization, and urgent heart failure visits in adults with heart failure (both reduced and preserved ejection fraction) 1
• Type 2 diabetes with cardiovascular disease/risk factors: To reduce heart failure hospitalization 1
• Glycemic control: As adjunct to diet and exercise in adults and pediatric patients aged ≥10 years with type 2 diabetes 1

Critical Limitations of Use

• NOT recommended for type 1 diabetes (markedly increases ketoacidosis risk) 1
• NOT recommended for glycemic control when eGFR <45 mL/min/1.73 m² (ineffective due to mechanism of action) 1
• NOT recommended for polycystic kidney disease or patients requiring/recently on immunosuppressive therapy for kidney disease (not expected to be effective) 1

Dosing Regimen

For Glycemic Control (Type 2 Diabetes)

• Starting dose: 5 mg orally once daily 1
• Titration: May increase to 10 mg once daily for additional glycemic control 1
• Renal considerations: Same dosing if eGFR ≥45 mL/min/1.73 m²; NOT recommended for glycemic control if eGFR <45 mL/min/1.73 m² 1

For All Other Indications (CKD, Heart Failure, CV Risk Reduction)

• Standard dose: 10 mg orally once daily 1
• Renal considerations: Same dosing if eGFR ≥25 mL/min/1.73 m²; do NOT initiate if eGFR <25 mL/min/1.73 m² 1
• If eGFR falls below 25 mL/min/1.73 m² while on treatment: Continue 10 mg daily to maintain cardiovascular and renal benefits 1

The American Association of Clinical Endocrinologists confirms this dosing strategy, noting that dapagliflozin can be used in combination with metformin, sitagliptin, and insulin 2.

Pre-Initiation Requirements

Before starting Farxiga, you must:

• Assess renal function (eGFR) and continue monitoring as clinically indicated 1
• Assess volume status: Correct any volume depletion before initiation, particularly in elderly patients, those with renal impairment, low systolic blood pressure, or on diuretics 1

Contraindications

Absolute contraindication: History of serious hypersensitivity reaction to dapagliflozin or any excipients (including anaphylaxis and angioedema) 1

Warnings and Precautions

Ketoacidosis (Most Critical Warning)

• In type 1 diabetes: Farxiga significantly increases ketoacidosis risk beyond background rates—this is a life-threatening event 1
• In type 2 diabetes: Fatal ketoacidosis cases reported postmarketing, particularly with precipitating factors 1
• Risk factors: Under-insulinization, insulin dose reduction/missed doses, acute illness, reduced caloric intake, ketogenic diet, surgery, volume depletion, alcohol abuse 1
• Presentation: May occur with blood glucose <250 mg/dL; symptoms include nausea, vomiting, abdominal pain, malaise, shortness of breath 1
• Management: Discontinue immediately if suspected, evaluate promptly, treat ketoacidosis, and monitor for resolution before restarting 1
• Withhold at least 3 days before major surgery or procedures with prolonged fasting to reduce ketoacidosis risk 1

The American College of Cardiology emphasizes this surgical precaution applies to all SGLT2 inhibitors 3.

Volume Depletion and Hypotension

• Higher risk in: Elderly patients, those with renal impairment (eGFR <60 mL/min/1.73 m²), low systolic blood pressure, or on diuretics 1
• Monitor for: Signs and symptoms of volume depletion during therapy 1
• Consider reducing diuretic doses when initiating Farxiga in patients on concurrent diuretics 3

Urosepsis and Pyelonephritis

• Evaluate promptly for signs/symptoms of urinary tract infections and treat if indicated 1
• The American College of Cardiology notes UTIs occur more frequently with SGLT2 inhibitors 3

Hypoglycemia Risk

• Intrinsic risk: Very low when used as monotherapy or with metformin (does not stimulate insulin secretion) 2
• Increased risk: When combined with insulin or insulin secretagogues (sulfonylureas, meglitinides) 2
• Prevention algorithm:
  • If patient is on insulin: Reduce insulin dose by 10-20% when initiating Farxiga 2
  • If patient is on sulfonylureas with HbA1c <8.5%: Strongly consider stopping the sulfonylurea 2
  • If patient is on complex insulin regimens: Involve endocrinology or primary care to prevent hypoglycemia 2
  • Patients without diabetes using Farxiga for heart failure or CKD have no hypoglycemia concern 2

Fournier's Gangrene (Necrotizing Fasciitis of the Perineum)

• Serious, life-threatening cases reported in both males and females with diabetes 1
• Assess patients with: Pain/tenderness, erythema, or swelling in genital/perineal area, along with fever or malaise 1
• If suspected: Institute prompt treatment 1

Genital Mycotic Infections

• Most common adverse reaction (≥5% incidence), particularly in women 1, 4
• Monitor and treat if indicated 1
• Kidney International notes these occur more frequently with SGLT2 inhibitors 3

Common Adverse Reactions (≥5% Incidence)

• Female genital mycotic infections 1
• Nasopharyngitis 1
• Urinary tract infections 1

Special Populations

Pregnancy

• Advise females of potential risk to fetus, especially during second and third trimesters 1

Lactation

• Not recommended when breastfeeding 1

Geriatrics

• Higher incidence of adverse reactions related to hypotension 1
• Assess volume status carefully before initiation 1

Renal Impairment

• Higher incidence of adverse reactions related to volume depletion 1
• For glycemic control: Not effective if eGFR <45 mL/min/1.73 m² 1
• For cardiovascular/renal indications: Continue if eGFR falls below 25 mL/min/1.73 m² while on treatment 1

Patient Counseling Recommendations

Ketoacidosis Education (Critical)

• Educate ALL patients on signs/symptoms of ketoacidosis: nausea, vomiting, abdominal pain, malaise, shortness of breath 1
• Instruct patients to discontinue Farxiga immediately and seek medical attention if these symptoms occur 1
• Emphasize that blood sugar may not be elevated despite ketoacidosis 1

Genital Infections

• Counsel on increased risk of genital mycotic infections, especially in women 1
• Advise to report symptoms for prompt treatment 1

Urinary Tract Infections

• Inform about increased UTI risk and importance of reporting symptoms 1

Volume Depletion

• Advise to maintain adequate hydration 1
• Report symptoms of dizziness, lightheadedness, or fainting 1

Surgical Procedures

• Instruct patients to inform healthcare providers they are taking Farxiga before any scheduled surgery 1
• Medication should be withheld at least 3 days before major surgery 1

Hypoglycemia (If on Insulin or Secretagogues)

• Counsel on recognizing hypoglycemia symptoms if taking insulin or sulfonylureas concurrently 2

Clinical Benefits Beyond Glycemic Control

The American Diabetes Association and American College of Cardiology highlight that dapagliflozin provides:

• Cardiovascular protection: Reduces cardiovascular death and heart failure hospitalization 2
• Renal protection: Reduces sustained eGFR decline and ESKD risk 2
• Weight reduction: Consistent weight loss across trials 2, 5
• Blood pressure reduction: Modest BP lowering effect 5

These benefits extend to patients with eGFR as low as 25 mL/min/1.73 m² for cardiovascular and renal indications 1.

Common Pitfalls to Avoid

• Do NOT discontinue Farxiga when eGFR falls below 45 mL/min/1.73 m² in patients already taking it for cardiovascular/renal indications—benefits persist 1
• Do NOT use for glycemic control in type 1 diabetes (markedly increases ketoacidosis risk) 1
• Do NOT forget to withhold at least 3 days before major surgery 1
• Do NOT overlook volume status assessment in elderly or renally impaired patients before initiation 1
• Do NOT fail to reduce insulin/sulfonylurea doses when adding Farxiga to prevent hypoglycemia 2